Merck and Oncosec will probably do a combo study for TNBC if the Combo study in melanoma is positive. I would advise people to keep an eye on Merck's expansion of Keytruda. Like a snowball, the more expansion of their oncology program with Keytruda will mean more bucks to spend on buyouts and partnerships. Merkel Cell and Head and Neck cancer combo studies with Keytruda could eventually be pursued down the road since Oncosec has proof of concept already in those indications. Lots of possibilities in the future besides melanoma.
News 
Market Data 
Discover 
